Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for ...

Merck has begun the 8% reduction of its workforce—an initiative that the company revealed two weeks ago—with the dismissal of ...

If you have decades to go before you retire, you want to make sure you own companies that know how to survive and thrive.

Merck’s second quarter performance aligned with Wall Street’s revenue expectations but drew a negative reaction from the ...

MSD, known as Merck & Co Inc in the United States and Canada, has been in Singapore for 30 years, employs over 1,800 people, ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

The research, done in mice and in human cells, shows that a protein called STUB1 restrains the immune system’s elite ...

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...

This week, Merck filed a notice in accordance with New Jersey's WARN Act, indicating it plans to eliminate 58 positions at ...

Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in ...

The pharmaceutical giant's journey with Celonis has evolved from operational efficiency to enabling enterprise AI ...